登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688710 证券简称：益诺思 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 注："本报告期"指本季度初至本季度末3个月期间，下同。 2025年以来，公司深度践行"以客户为中心"的服务理念，精准洞察客户需求，以组织变革为抓手，加大 国内外市场开拓力度，通过在核心业务领域精耕细作，公司第三季度营业收入环比增长17.71%。2025 年前三季度，公司订单规模与业务质量实现同步提升，订单储备呈现稳中有进态势，新签订单金额同比 增长29.37%，其中公司核心业务新药临床试验申请（IND） ...

Group 1 - The core point of the announcement is the resolution of the third extraordinary general meeting of shareholders held by Shanghai Yinos Biotech Co., Ltd., confirming that there were no rejected proposals [1] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with a combination of on-site and online voting methods [2] - All current directors and supervisors attended the meeting, ensuring full representation of the board [3] Group 2 - Two key proposals were approved during the meeting: the reappointment of the accounting firm and the purchase of directors and officers liability insurance [4] - The meeting was held on September 23, 2025, at the designated location in Shanghai [4] - The voting results indicated that all proposals received more than half of the valid voting rights from attending shareholders, with separate counting for minority investors [5] Group 3 - The meeting was witnessed by lawyers from Guohao Law Firm, confirming that the procedures and voting methods adhered to legal requirements [5]

长江日报讯（记者黄琪 谭芳）9月18日，省委常委、市委书记郭元强到江夏 区调研大健康和生物技术产业发展。他强调，要深入学习贯彻习近平总书记考察湖 北重要讲话精神，认真落实省委、省政府部署要求，坚持以科技创新引领产业创 新，推动大健康和生物技术产业高质量发展，为武汉打造国际医疗创新高地作出更 大贡献。 武汉睿锶生物技术有限公司是一家致力于先进表观基因组学技术创新的高技术 企业，主要为科研机构及企业提供基因组学实验技术服务及相关产品。郭元强来到 这里，详细了解企业技术创新和产业化应用情况。他勉励企业瞄准市场需求，持续 加强技术攻关，增强企业核心竞争力，拓展多维基因组技术在农业和医学等领域的 应用。 郭元强在调研中强调，大健康和生物技术产业是战略性新兴产业的重要发展方 向，是我市的优势产业、支柱产业之一。江夏区作为大健康和生物技术产业的重要 集聚区，要高度重视、扛牢责任，结合"十五五"规划编制，深入谋划产业发展的重 点方向、重大项目、重要举措，加强与光谷生物城协同联动，充分调动各类资源， 推动产业提质升级、壮大规模，塑造发展新动能新优势。要着力推动科技创新和产 业创新融合发展，加强创新资源统筹和力量组织，顺应人工智 ...

9月18日，省委常委、市委书记郭元强到江夏区调研大健康和生物技术产业发展。他强 调，要深入学习贯彻习近平总书记考察湖北重要讲话精神，认真落实省委、省政府部署要 求，坚持以科技创新引领产业创新，推动大健康和生物技术产业高质量发展，为武汉打造国 际医疗创新高地作出更大贡献。 药谷之星项目位于江夏区郑店街凤栖湖畔，规划打造成光谷南大健康产业园的综合商务 区。郭元强实地察看项目建设进展，了解药谷"人产城"融合发展情况。他强调，要高质量高 标准推进项目建设，完善公共服务、商业配套、生活服务功能，同步推进招商引资工作，推 动人才、技术、资本等要素加速集聚，打造产城融合、宜居宜业的现代化园区。 武汉睿锶生物技术有限公司是一家致力于先进表观基因组学技术创新的高技术企业，主 要为科研机构及企业提供基因组学实验技术服务及相关产品。郭元强来到这里，详细了解企 业技术创新和产业化应用情况。他勉励企业瞄准市场需求，持续加强技术攻关，增强企业核 心竞争力，拓展多维基因组技术在农业和医学等领域的应用。 郭元强在调研中强调，大健康和生物技术产业是战略性新兴产业的重要发展方向，是我 市的优势产业、支柱产业之一。江夏区作为大健康和生物技术产业的 ...

Core Viewpoint - The company Jabiou has decided to terminate its acquisition plan for a stake in Ouyi Biotechnology due to changes in the external market environment and after thorough communication with relevant parties [2][3]. Group 1: Acquisition Plan - Jabiou initially planned to acquire 63.21% of Ouyi Biotechnology's shares for approximately 831 million yuan, while also issuing shares to raise matching funds from no more than 35 specific investors [2]. - The acquisition was notable due to an asset appraisal increase of 441.23%, which would have resulted in a goodwill increase of 721 million yuan for Jabiou [2]. - The acquisition plan underwent several adjustments, including a reduction in the stake from 65% to 63.21% and changes in the performance compensation calculation method [2][3]. Group 2: Business Operations - Despite the termination of the acquisition, Jabiou stated that its business operations remain normal and that the decision will not adversely affect daily operations or harm the interests of shareholders, particularly minority shareholders [3]. - The company continues to focus on its strategic goals and aims to enhance its synthetic biology technology system, including omics technology [3]. - In the first half of the year, Jabiou reported a revenue of 307 million yuan, representing a year-on-year growth of 17.6%, and a net profit attributable to shareholders of 108 million yuan, reflecting a 59.01% increase [3].

Core Viewpoint - Zhejiang Tailin Biological Technology Co., Ltd. is implementing an employee stock ownership plan (ESOP) for 2025, which has been reviewed and approved by the legal counsel, Grandall Law Firm (Hangzhou) [2][15]. Group 1: Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. is a legally established and effectively existing joint-stock company with a registered capital of 108.67663 million yuan [4]. - The company is listed on the Shenzhen Stock Exchange's Growth Enterprise Market, with its stock code being 300813, and it was officially listed on January 14, 2020 [5][7]. Group 2: Employee Stock Ownership Plan (ESOP) Details - The ESOP was approved during the fourth board meeting on March 11, 2025, and complies with relevant laws and regulations [8][15]. - The plan allows employees to voluntarily participate, ensuring no forced participation or financial assistance from the company [9][14]. - The stock acquired through the ESOP will have a lock-up period of 12, 24, and 36 months, with specific unlocking ratios of 40%, 30%, and 30% respectively [10]. Group 3: Legal Compliance and Procedures - The legal opinion confirms that the company has fulfilled necessary legal procedures for the ESOP, including obtaining approvals from the board and supervisory committee [12][15]. - The company must still hold a shareholders' meeting to approve the ESOP and disclose the legal opinion two trading days prior to the meeting [15][18]. - The ESOP does not create a concerted action relationship with controlling shareholders or management, ensuring compliance with relevant regulations [17]. Group 4: Information Disclosure - The company has disclosed the ESOP draft, management measures, and relevant resolutions through designated media [17][18]. - Ongoing information disclosure obligations will continue as the ESOP progresses, in accordance with regulatory requirements [18].